Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice

Infection and Immunity

Volumn 76, Issue 9, 2008, Pages 4088-4091

  Murray, Henry W ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; GAMMA INTERFERON; INTERLEUKIN 6; STIBOGLUCONATE SODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GRANULOMA; INFECTION CONTROL; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; WILD TYPE;

ANIMALS; ANTIPROTOZOAL AGENTS; FEMALE; GRANULOMA; INTERFERON TYPE II; INTERLEUKIN-6; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 51949114852     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00490-08     Document Type: Article

References (46)

1. Akilov, O. E., S. Kosaka, K. O'Riordan, and T. Hasan. 2007. Parasiticidal effect of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of host cells. Exp. Dermatol. 16:651-660.
2. Ansari, N. A., S. Saluja, and P. Salotra. 2006. Elevated levels of interferon-γ. interleukin-10 and interleukin-6 during active disease in Indian kala azar. Clin. Immunol. 119:339-345.
3. Ansari, N. A., V. Ramesh, and P. Salotra. 2006. Interferon (IFN)-γ, tumor necrosis factor-α, interleukin-6, and IFN-γ receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J. Infect. Dis. 194:958-965.
4. Awasthi, A., Y. Carrier, J. P. S. Peron, E. Bettelli, M. Kamanaka, R. A. Flavell, V. K. Kuchroo, M. Oukka, and H. L. Weiner. 2007. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8:1380-1389.
5. Beaman, M. H., C. A. Hunter, and J. S. Remington. 1994. Enhancement of intracellular replication of Toxoplasma gondii by IL-6: interactions with IFN-γ and TNF-α. J. Immunol. 153:4583-4588.
6. Bermudez, L. E., M. Wu, M. Petrofsky, and L. S. Young. 1992. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and myco-bactericidal activities in macrophages. Infect. Immun. 60:4245-4252.
7. Bongartz, T. 2008. Tocilizumab for rheumatoid and juvenile idiopathic arthritis. Lancet 371:961-963.
8. Caceres-Dittmar, G., F. J. Tapia, M. A. Sanchez, M. Yamamura, K. Uve-mure, R. L. Modlin, B. R. Bloom, and J. Convit. 1993. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin. Exp. Immunol. 91:500-505.
9. Castellucci, L., E. Menezes, J. Oliveira, A. Magalhaes, L. H. Guimaraes, M. Lessa, S. Ribeiro, J. Reale, E. F. Noronha, M. E. Wilson, P. Duggal, T. H. Beaty, S. Jeronimo, S. E. Jamieson, A. Bales, J. M. Blackwell, A. Ribeiro de Jesus, and E. M. Carvalho. 2006. IL6-174G/C promoter polymorphism influences susceptibility to mucosal hut not localized cutaneous leishmaniasis in Brazil. J. Infect. Dis. 194:519-527.
10. Cenini, P., N. Berhe, A. Hailu, K. McGinnes, and D. Frommel. 1993. Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J. Infect. Dis. 168:986-993.
11. de Lima, V. Id., J. R. Peiro, and R. de Oliveira Vasconcelos. 2007. IL-6 and TNF-alpha production during active canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 115:189-193.
12. de Miranda Santos, I. K. F., C. H. N. Costa, H. Kreiger, M. F. Feitosa, D. Zurakowski, B. Fardin, R. B. B. Gomes, D. L. Weiner, D. A. Harn, R. A. B. Ezekowitz, and J. E. Epstein. 2001. Mannan-binding lectin enhances susceptibility to visceral leishmaniasis. Infect. Immun. 69:5212-5215.
13. Diehl, S., ani M. Rincon. 2002. The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. 39:531-536.
14. Fitzgerald, D. C., G.-X. Zhang, M. El-Behi, Z. Fonesca-Kelly, H. Li, S. Yu, C. J. M. Saris, B. Gran, B. Ciric, and A. Rostami. 2007. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by nterleukin 27-stimulated T cells. Nat. Immunol. 8:1372-1379.
15. Galindo-Sevilla, N., N. Soto, J. Mancilla, A. Cerbulo, E. Zambrano, R. Chavira, and J. Huerto. 2007. Low serum levels of dehydroepiandrosterone and Cortisol in human diffuse cutaneous leishmaniasis by Leishmania mexicana. Am. J. Trop. Med. Hyg. 76:566-572.
16. Hatzigeorgiou, D. E., S. He, J. Sobel, K. H. Grabstein, A. Hafner, and J. L. Ho. 1993. IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. J. Immunol. 151:3682-3692.
17. Karam, M. C., H. G. Hamdan, N. A. Abi Chedid, K. B. Bodman-Smith, and G. M. BaroDdy. 2007. Interleukin-10 reduces hyperalgesia and the level of interleukin-1β in BALB/c mice infected with Leishmania major with no major effec: on the level of interleukin-6. J. Neuroimmunol. 183:43-49.
18. Kishimoto, T. 2005. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu. Rev. Immunol. 23:1-21.
19. Kocyigit, A., S. Gur, M. S. Gurel, V. Bulut, and M. Ulukanligil. 2002. Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis. Infect. Immun. 70:6589-6591.
20. Louzir, H., P. C. Melby, A. Ben Salah, H. Marrakchi, K. Aoun, R. Ben Ismail, and K. Dellaqi. 1998. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J. Infect. Dis. 177:1687-1695.
21. H-17 cell-mediated pathology. Nat. Immunol. 8:1390-1397.
22. Melby, P. C., F. J. Andrade-Narvaez, B. J. Darnell, G. Valencia-Pacheco, V. V. Tyron, and A. Palomo-Cetina. 1994. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 62:837-842.
23. Moskowitz, N. H., D. R. Brown, and S. L. Reiner. 1997. Efficient immunity against Leishmania major in the absence of interleukin-6. Infect. Immun. 65:2448-2450.
24. Murphy, M. L., U. Wille, E. N. Villegas, C. A. Hunter, and J. P. Farrell. 2001. IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 31:2848-2856.
25. Murray, H. W., and C. F. Nathan. 1999. Macrophage microbicidal mechanisms in v vo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189:741-746.
26. Murray, H. W. 2000. Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation. Infect. Immun. 68:6294-6299.
27. Murray, H. W., and S. Delph-Etienne. 2000. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68:288-293.
28. Murray, H. W. 2001. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int. J. Exp. Pathol. 82:249-267.
29. Murray, H. W., C. M. Lu, S. Mauze, S. Freeman, A. L. Moreira, G. Kaplan, and R. L. Coffman. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70:6284-6293.
30. Murray, H. W., E. B. Brooks, J. L. DeVecchio, and F. P. Heinzel. 2003. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 47:2513-2517.
31. Murray, H. W., K. C. Flanders, D. D. Donaldson, J. P. Sypek, P. J. Gotwals, J. Liu, and X. Ma. 2005. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 73:3903-3911.
32. Murray, H. W., C. W. Tsai, J. Liu, and X. Ma. 2006. Responses to Leishmania donovani in mice deficient in interkeukin-12 (IL-12), IL-12/IL-23, or IL-18. Infect. Immun. 74:4370-4374.
33. Nagabhushanam, V., A. Solache, L.-M. Ting, C. J. Escaron, J. Y. Zhang, and J. D. Ernst. 2003. Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-γ. J. Immunol. 171:4750-4757.
34. + monocytes are hallmarks of active human visceral leishmaniasis due to Leishmania chagasi infection. Clin. Exp. Immunol. 146:124-132.
35. + T cells. J. Exp. Med. 185:461-469.
36. Rosas, L. E., A. A. Satoskar, K. M. Roth, T. L. Reiser, J. Barbi, C. Hunter, F. J. de Sauvage, and A. R. Satoskar. 2006. IL-12R (WSX-1/TCCR) gene-deficient mice display enhanced resistance to Leishmania donovani but develop severe liver immunopathology. Am. J. Pathol. 168:158-166.
37. Saha, B., A. Saini, R. Germond, P. J. Perrin, D. M. Harlan, and T. A. Davis. 1999. Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF. Eur. J. Immunol. 29:2319-2329.
38. Satoskar, A. R., M. Bozza, M. Rodriguez Sosa, G. Lin, and J. R. David. 2001. Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect. Immun. 69:906-911.
39. Satoskar, A. R., S. Rodig, S. R. Telford, A. A. Satoskar, S. K. Ghosh, F. von Lichtenberg, and J. R. David. 2000. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic pathology. Eur. J. Immunol. 30:834-839.
40. + T cells. Eur. J. Immunol. 36:1764-1771.
41. Stumhofer, J. S., J. S. Silver, A. Laurence, P. M. Porrett, T. H. Harris, L. A. Turka, M. Ernst, C. J. M. Saris, J. J. O'Shea, and C. A. Hunter. 2007. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8:1363-1371.
42. Titus, R. G., G. K. DeKrey, R. V. Morris, and M. B. P. Soares. 2001. Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease. Infect. Immun. 69:5189-5192.
43. Tumang, M. C. T., C. Keogh, L. L. Moldawer, D. C. Helfgott, R. Teitelbaum, J. Hariprashad, and H. W. Murray. 1994. Role and effect of TNF-α in experimental visceral leishmaniasis. J. Immunol. 153:768-775.
44. van der Poll, T., E. E. Zijlstra, and M. Mevissen. 1995. Interleukin 6 during active visceral leishmaniasis and after treatment. Clin. Immunol. Immunopathol. 77:111-114.
45. Wilson, M. E., M. Sandor, A. M. Blum, B. M. Young, A. Metwali, D. Elliott, R. G. Lynch, and J. V. Weinstock. 1996. Local suppression of IFN-γ in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J. Immunol. 156:2231-2239.
46. Wu, W., L. Weigand, Y. Belkaid, and S. Mendez. 2006. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides. Eur. J. Immunol. 36:3238-3247.